United Laboratories International Holdings Ltd/The EBITDA Margin dropped on 19.0 pp from 19.0% to in 2016
22/03/2017 • About United Laboratories International Holdings Ltd/The (
$3933) • By InTwits
United Laboratories International Holdings Ltd/The reported FY2016 financial results today. Overall the company's long term financial model is characterised by the following facts: It operates with high leverage: Net Debt/EBITDA is 3.8x while industry average is -1.4x.
Below you can find a comprehensive analysis of the key data driving the company's performance and stock price.
United Laboratories International Holdings Ltd/The ($3933) key annual financial indicators
| mln. HKD | 2012 | 2013 | 2014 | 2015 | 2016 | 2016/2015 |
|---|
P&L
|
|---|
| Revenue | 7,022 | 7,648 | 8,030 | 7,695 | 7,063 | -8.2% |
| Gross Profit | 2,117 | 2,638 | 3,228 | 2,961 | | -100.0% |
| SG&A | 1,672 | 1,787 | 1,971 | 2,024 | | -100.0% |
| EBITDA | 985 | 1,639 | 1,723 | 1,458 | | -100.0% |
| Net Income | 162 | 48 | 681 | 110 | -311 | -382.1% |
Balance Sheet
|
|---|
| Cash | 646 | 1,081 | 1,003 | 1,115 | | -100.0% |
| Short Term Debt | 6,044 | 6,446 | 6,036 | 5,549 | | -100.0% |
| Long Term Debt | 1,023 | 2,165 | 2,163 | 1,420 | | -100.0% |
Cash flow
|
|---|
| Capex | 2,777 | 2,046 | 692 | 723 | | -100.0% |
Ratios
|
|---|
| Revenue growth | 9.6% | 8.9% | 5.0% | -4.2% | -8.2% | |
| EBITDA growth | 28.4% | 66.5% | 5.1% | -15.4% | | |
| Gross Margin | 30.2% | 34.5% | 40.2% | 38.5% | | -38.5% |
| EBITDA Margin | 14.0% | 21.4% | 21.5% | 19.0% | 0.0% | -19.0% |
| Net Income Margin | 2.3% | 0.6% | 8.5% | 1.4% | -4.4% | -5.8% |
| SG&A, % of revenue | 23.8% | 23.4% | 24.5% | 26.3% | | -26.3% |
| CAPEX, % of revenue | 39.6% | 26.8% | 8.6% | 9.4% | | -9.4% |
| ROIC | 3.9% | 7.3% | 6.3% | 4.2% | | -4.2% |
| ROE | 2.9% | 0.8% | 10.1% | 1.6% | | -1.6% |
| Net Debt/EBITDA | 6.5x | 4.6x | 4.2x | 4.0x | | -4.0x |
Revenue and profitability
The company's Revenue decreased on 8.2%.
Net Income marign decreased on 5.8 pp from 1.4% to -4.4% in FY2016.
Appendix 1: Peers in Pharmaceuticals
Below we provide United Laboratories International Holdings Ltd/The benchmarking against other companies in Pharmaceuticals industry for the last 5 years. We show data for the top-5 companies by key financial metric together with the median value for all the companies in the industry.
Top companies by Revenue growth, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| China Health Group Inc ($8225) | 58.5% | -48.0% | -60.1% | 244.1% | |
| Wai Yuen Tong Medicine Holdings Ltd ($897) | | 45.9% | -10.5% | 105.6% | 40.9% |
| Oriental Unicorn Agricultural Group Ltd ($8120) | 30.2% | -78.1% | 16.8% | 100.8% | |
| China Traditional Chinese Medicine Co Ltd ($570) | | 35.2% | 90.0% | 40.0% | 76.1% |
| RM Group Holdings Ltd ($8185) | | 4.6% | -16.0% | 34.2% | -16.6% |
| |
|---|
| Median (41 companies) | 16.2% | 13.5% | 15.3% | 4.0% | 10.8% |
|---|
| United Laboratories International Holdings Ltd/The ($3933) | | 8.9% | 5.0% | -4.2% | -8.2% |
Top companies by Gross margin, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Luye Pharma Group Ltd ($2186) | 83.5% | 83.6% | 81.0% | 81.4% | |
| Consun Pharmaceutical Group Ltd ($1681) | 75.7% | 79.1% | 78.3% | 80.7% | |
| Jilin Province Huinan Changlong Bio-pharmacy Co Ltd ($8049) | 82.0% | 81.5% | 80.9% | 79.9% | |
| RM Group Holdings Ltd ($8185) | 79.6% | 78.8% | 76.6% | 77.7% | 77.4% |
| Sino Biopharmaceutical Ltd ($1177) | 78.5% | 77.5% | 76.4% | 77.7% | 79.2% |
| |
|---|
| Median (40 companies) | 42.5% | 41.1% | 52.2% | 50.0% | 51.0% |
|---|
| United Laboratories International Holdings Ltd/The ($3933) | 30.2% | 34.5% | 40.2% | 38.5% | |
Top companies by EBITDA margin, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Northeast Tiger Pharmaceutical Corp Ltd ($8197) | 193.8% | 205,840.0% | -15,344.8% | 49,650.0% | 26.0% |
| Sihuan Pharmaceutical Holdings Group Ltd ($460) | 38.8% | 65.4% | 70.9% | 93.3% | |
| Hua Han Bio-Pharmaceutical Holdings Ltd ($587) | 60.6% | 21.0% | 28.8% | 61.1% | |
| U-Home Group Holdings Ltd ($2327) | 9.8% | -16.6% | -46.7% | 51.7% | |
| Beijing Tong Ren Tang Chinese Medicine Co Ltd ($8138) | 41.3% | 45.4% | 47.5% | 49.1% | 50.9% |
| |
|---|
| Median (41 companies) | 20.7% | 20.2% | 21.4% | 21.0% | 11.2% |
|---|
| United Laboratories International Holdings Ltd/The ($3933) | 14.0% | 21.4% | 21.5% | 19.0% | |
Top companies by CAPEX/Revenue, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Hao Wen Holdings Ltd ($8019) | 30.0% | 2.3% | 38.2% | 44.8% | |
| Hua Han Bio-Pharmaceutical Holdings Ltd ($587) | 0.9% | 1.4% | 7.6% | 40.5% | |
| Lee's Pharmaceutical Holdings Ltd ($950) | 18.6% | 20.9% | 7.1% | 26.1% | |
| Tianda Pharmaceuticals Ltd ($455) | 6.0% | 3.9% | 10.5% | 24.4% | 22.9% |
| Lijun International Pharmaceutical Holding Co Ltd ($2005) | 16.8% | 52.4% | 39.6% | 18.7% | |
| |
|---|
| Median (40 companies) | 8.2% | 8.1% | 7.4% | 4.5% | 2.8% |
|---|
| United Laboratories International Holdings Ltd/The ($3933) | 39.6% | 26.8% | 8.6% | 9.4% | |
Top companies by ROIC, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Sino Biopharmaceutical Ltd ($1177) | 26.2% | 26.8% | 26.5% | 26.2% | 24.3% |
| Beijing Tong Ren Tang Chinese Medicine Co Ltd ($8138) | 25.3% | 27.5% | 23.8% | 25.9% | 25.1% |
| Sihuan Pharmaceutical Holdings Group Ltd ($460) | 13.7% | 18.3% | 22.0% | 25.4% | |
| Dawnrays Pharmaceutical Holdings Ltd ($2348) | 12.6% | 14.0% | 17.8% | 23.5% | |
| Lee's Pharmaceutical Holdings Ltd ($950) | 26.1% | 22.0% | 22.4% | 22.7% | |
| |
|---|
| Median (42 companies) | 12.3% | 9.3% | 11.1% | 10.9% | 5.0% |
|---|
| United Laboratories International Holdings Ltd/The ($3933) | 3.9% | 7.3% | 6.3% | 4.2% | |
Top companies by Net Debt / EBITDA
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Northeast Tiger Pharmaceutical Corp Ltd ($8197) | 2.3x | 3.7x | | 22.2x | -5.1x |
| U-Home Group Holdings Ltd ($2327) | 10.1x | | | 9.9x | |
| Lansen Pharmaceutical Holdings Ltd ($503) | 1.7x | 2.8x | 3.4x | 4.7x | |
| China Grand Pharmaceutical and Healthcare Holdings Ltd ($512) | 5.4x | 4.0x | 3.4x | 4.3x | |
| Shandong Xinhua Pharmaceutical Co Ltd ($719) | 3.5x | 3.4x | 2.8x | 3.4x | 2.7x |
| |
|---|
| Median (34 companies) | -0.4x | -0.5x | -0.7x | -0.6x | -1.4x |
|---|
| United Laboratories International Holdings Ltd/The ($3933) | 6.5x | 4.6x | 4.2x | 4.0x | |
